Drug merger not expected to have big impact on N.J.

November 24, 2015

James Hughes, dean of the Bloustein School of Planning & Public Policy at Rutgers University, also said he did not see much duplication to be cut.

“Allergan has a sales staff that deals with their specific products, and Pfizer has its staff for different products. So I would think that staff is going to stay intact,” Hughes said. “It shouldn’t have much of an impact one way or the other on New Jersey.”

Wall Street Journal, November 23

Recent Posts

Sophia Jones, Committed to Cultural Competence

Sophia Jones, PhD, has been a Public Health part-time lecturer at the Bloustein School since 2016. She was recently featured on "Meet the People of Rutgers." Sophia Jones, Committed to Cultural Competence Jeff Arban/Rutgers University The Basics Title: Program...

Upcoming Events

Event Series CAREERS

Career Virtual Drop-ins


Bloustein Career Development Specialists Cheryl Egan and Andrea Garrido will be in a Zoom Room on Monday's beginning January 22, 2024 (excluding holidays and spring break) to answer questions, provide […]